Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PersonGen BCMA CAR-T in R/R Multiple Myeloma
NCT04650724Phase 1Completed
- Sponsor
- PersonGen BioTherapeutics
- Start
- Oct 2018
- Primary completion
- Dec 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PA-CART-BCMA-001 in multiple myeloma (MM), sponsored by PersonGen BioTherapeutics. Primary endpoints: Incidence of Adverse Events or Serious Adverse Events at 12 weeks and Objective Response Rate at 12 weeks. Started Oct 2018; status: completed.
02
Drugs
PA-CART-BCMA-001
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04650724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04650724.